why choose us

First received: September 21, 2022

Clinical Trial: RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma

Study Status: ACTIVE_NOT_RECRUITING

Recruit Status: ACTIVE_NOT_RECRUITING

Condition: Glioblastoma

Study Type: INTERVENTIONAL


Official Title: A Phase I/Ib, Open-Label, Dose-Escalation Study of RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma

Brief Summary: This phase I/Ib trial tests the side effects, best dose, tolerability, and effectiveness of RMC-5552 in treating patients with glioblastoma that has come back (recurrent).RMC-5552 is a type of medicine called an mechanistic target of rapamycin (mTOR) inhibitor.These types of drugs prevent the formation of a specific group of proteins called mTOR.This protein controls cancer cell growth, and the study doctors believe stopping mTOR from forming may help to kill tumor cells.

Read more